AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$STAA

STAAR Surgical (NASDAQ:STAA) reports strong Q3 2026

STAAR Surgical reported Q3 2026 revenue of $83.41M, beating estimates by 6.7%. EPS of $0.11 exceeded forecasts, and adjusted EBITDA was $14.36M, a 19.5% beat. Operating margin declined to 6.5%, while free cash flow margin rose to 31.6%.

Original reporting
finance.yahoo.com
Published Nov 4, 2026, 9:27 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
STAAR Surgical (NASDAQ:STAA) reports strong Q3 2026 — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$STAABullishHigh
01

Why it matters

The earnings beat could attract short‑term buying interest and improve sentiment toward the niche ophthalmic market.

02

Market read

First‑report earnings with beats on both top‑line and EPS for a micro‑cap healthcare stock.

03

What to watch

Guidance for Q4 is not provided; margin compression year‑on‑year could limit upside.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

STAAR Surgical (NASDAQ:STAA) is a medical device company focused on ophthalmic surgery tools.

Company-level read

Ticker impact

$STAABullishHigh confidence
Context

STAAR Surgical reported Q3 2026 revenue of $83.41M beating $78.17M consensus and EPS $0.11 beating $0.05 consensus.

Expected impact

likely upside as market prices in the earnings beat

Evidence & confidence

Both revenue and EPS exceeded expectations, and free cash flow margin improved dramatically, supporting a bullish reaction.

Market effects

Sector

Positive signal for the medical device sector, may lift peers.

Regional

U.S. small‑cap healthcare stocks could see modest gains.

Global

Limited to U.S. markets; no broader global effect.

Counterpoint

What could challenge this read

The beat may be priced in quickly, leading to a short‑term pullback.

Key entities

  • Company
    STAAR Surgical

    Medical device maker reporting Q3 2026 results.

Read at source← All news

StorySTAAR Surgical posts strong Q3 2026 results and launches $50 M share buyback

Also covered by

2 outlets

Related articles

$STAAHighAI 8/10

STAAR Surgical (STAA) Q3 2026 Earnings Call Transcript

STAAR Surgical (STAA) reported Q3 2026 revenue growth of 31% excluding prior-year adjustments, driven by EVO+ lens adoption in China and global market expansion. Gross margin was impacted by temporary factors but is expected to improve. The company announced a $50M share repurchase program and plans for new product trials. Asia Pacific, EMEA, and Americas regions showed varied growth, with China being the largest market.

finance.yahoo.com
$STAAHigh

STAAR Surgical Reports Third Quarter 2026 Results

STAAR SURGICAL CO (STAA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 STAAR Surgical Reports Third Quarter 2026 Results Net Sales of $83.4 Million in the Third Quarter Net Income of $5.6 Million, with GAAP EPS of $0.11 Adjusted EBITDA [1] of $14.4 Million, or $0.28 per Diluted Share Record Revenue of $270.5 Million in the First Three Q

SEC EDGAR 8-K
$STAAMedAI 9/10

Overseas Investors, Local Philanthropy

SoftBank Group is in early talks to acquire Allied Universal for $30B ($18B equity, $12B debt). Allied, with $22.6B revenue, is a security firm with 800,000 employees. SoftBank's interest aligns with its AI and robotics ambitions, according to Reuters. Allied's CEO Steve Jones has focused on tech advances, including robotics. SoftBank's local investments include Sprint Corp. and Kingston Technology, with mixed outcomes.

ocbj.com
$STAAHigh

Why Staar Surgical Zoomed Almost 8% Higher on Tuesday

Staar Surgical (STAA) shares rose nearly 8% after Stifel's Thomas Stephan upgraded the stock to buy from hold, raising the price target to $31. He cited positive sales momentum, particularly in China, and potential for acquisitions. The company's FDA-approved products and lean operations were also highlighted.

aol.com
$STAAHigh

Why is STAAR Surgical stock surging today?

STAAR Surgical (STAA) stock rose 8.8% after Stifel upgraded it to Buy, raising its price target to $31. The firm cited a favorable product mix shift and easier comparisons, projecting 11% sales growth through 2028. The company also announced a $50M share buyback program, signaling confidence in its financial strength.

investing.com